NovoCure 2026 Revenue Split: Optune Pax, Lua, and Gio Breakdown

Analysis of Expected 2026 Revenue Split for Optune Pax, Optune Lua, and Optune Gio

NovoCure’s guidance and commentary from the Q4 2025 earnings call and related disclosures provide key insights into the expected revenue contributions of its three primary products for 2026: Optune Pax, Optune Lua, and Optune Gio.

---

Total 2026 Revenue Guidance

• Total net revenue guidance (at constant exchange rates): $675 million to $705 million
• Implied growth: 3% to 8% over 2025 revenue of $655 million ¹².

---

Breakdown and Assumptions From Management Commentary

1. Optune Gio (Glioblastoma Multiforme - GBM product)

   • Expected to grow in the low to mid-single-digit range in 2026.
   • This product remains the core revenue driver and is described as mature with steady active patient growth, especially in established markets (U.S., Germany, France, Japan).
   • 2025 estimated typical growth was mid-single digits with approximately 40% patient penetration in mature markets, with room for growth ³⁴.
   • New launches in Spain, Czechia, and British Columbia will add modest revenues in 2026, contributing to the growth narrative but not significantly recovering to large revenue numbers yet ³⁵.

2. Optune Lua (Non-Small Cell Lung Cancer)

   • Currently contributing to revenue in 2025: ~$10.4 million total revenue with $5.8 million from NSCLC patients specifically ².
   • The 2026 guidance includes combined revenues of $15 million to $25 million from "non-GBM products", which encompasses both Optune Lua and Optune Pax ¹.
   • Optune Lua’s launch in Japan is anticipated to receive final reimbursement soon, presenting growth opportunities there.
   • The product launch pace in the U.S. and Germany has been slower than initially expected and marketing spend has been adjusted accordingly ⁴.

3. Optune Pax (Locally Advanced Pancreatic Cancer)

   • FDA approval received early in 2026 with an immediate launch underway in the U.S. leveraging the existing torso sales force from Optune Lua.
   • Expected to build a foundation in 2026, with significant scale-up in subsequent years given a highly motivated patient population (~15,000 patients annually in the U.S. for locally advanced pancreatic cancer) and limited treatment alternatives ⁶⁴.
   • Revenue contribution is included within the $15 million to $25 million range allotted to non-GBM products (Optune Lua + Optune Pax).
   • Coverage and reimbursement ramp expected to take 1–2 years, impacting near-term revenue realization for Optune Pax ⁷⁸.
   • At launch, revenue recognition may lag behind patient starts due to the appeals and reimbursement process ⁷.

---

Quantitative Revenue Split Estimates for 2026

*Note: The bulk of NovoCure’s revenue remains driven by GBM/Optune Gio, since total 2025 revenue was $655 million, with non-GBM revenue only about $10 million. The 2026 guidance anticipates $15 million to $25 million for non-GBM (Optune Lua + Pax), so Optune Gio remains about 90%+ of total revenue.

---

Summary

• Optune Gio will continue to be NovoCure’s main revenue source in 2026, expected to generate roughly ~$635 million to $660 million, reflecting the base business with low to mid-single-digit growth.
• Non-GBM products, namely Optune Lua and Optune Pax together are expected to contribute $15 million to $25 million in net revenue, with Optune Pax ramping up from launch and Optune Lua growing principally via new market expansions such as Japan.
• The company explicitly states that they expect Optune Pax revenues to gain steam beyond 2026, given coverage uptake timelines of 1-2 years and significant addressing of an unmet need in pancreatic cancer ¹⁶⁷⁸.
• NovoCure’s strategy to leverage existing sales infrastructure for Pax launch reduces incremental expenses, supporting profitable scaling of non-GBM products ⁷⁸.

---

Conclusion

In quantitative terms, NovoCure’s 2026 revenue split is approximately:

• Optune Gio: ~$635M–$660M (majority of total revenues)
• Optune Lua + Optune Pax: $15M–$25M combined (with Pax still nascent but ramping)

This reflects a business still heavily reliant on GBM but diversifying meaningfully, with the non-GBM products representing a growing but smaller slice, reflecting early-stage launches and reimbursement processes ^1367428.

---

This financial analysis incorporates NovoCure’s disclosed 2025 results, growth expectations by product line, and guidance commentary for 2026, providing a transparent view of the revenue contribution and growth trajectory across its core product portfolio.